Functional defects in the Fanconi anemia pathway in pancreatic cancer cells

American Journal of Pathology

Volumn 165, Issue 2, 2004, Pages 651-657

  Van Der Heijden, Michiel S ^a   Brody, Jonathan R ^a   Gallmeier, Eike ^a   Cunningham, Steven C ^a   Dezentje, David A ^a   Shen, Dong ^a   Hruban, Ralph H ^a   Kern, Scott E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MITOMYCIN C;

ARTICLE; CANCER CELL; CELL CYCLE; CELL SURVIVAL; CONTROLLED STUDY; CROSS LINKING; FANCONI ANEMIA; GENE MUTATION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; UBIQUITINATION;

EID: 3242789247     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63329-9     Document Type: Article

References (33)

1. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D'Andrea AD: Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002, 297:606-609
2. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, Yeo CJ, Jackson CE, Lynch HT, Hruban RH, Kern SE: Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996, 56:5360-5364
3. Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, Hruban RH, Kern SE: Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002, 62:3789-3793
4. Figer A, Irmin L, Geva R, Flex D, Sulkes J, Sulkes A, Friedman E: The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. Br J Cancer 2001, 84:478-481
5. Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, Gerdes B, Kress R, Ziegler A, Raeburn JA, Campra D, Grutzmann R. Rehder H, Rothmund M, Schmiegel W, Neoptolemos JP, Bartsch DK: BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003, 95:214-221
6. van der Heijden MS, Yeo CJ, Hruban RH, Kern SE: Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003, 63:2585-2588
7. Sadoff L, Latino F: Complete clinical remission in a patient with advanced pancreatic cancer using mitomycin C-based chemotherapy: the role of adjunctive heparin. Am J Clin Oncol 1999, 22:187-190
8. Takada T, Nimura Y, Katoh H, Nagakawa T, Nakayama T, Matsushiro T, Amano H, Wada K: Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. Hepatogastroenterology 1998, 45:2020-2026
9. Todd KE, Gloor B, Lane JS, Isacoff WH, Reber HA: Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole. J Gastrointest Surg 1998, 2:159-166
10. Moynahan ME, Cui TY, Jasin M: Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brcal mutation. Cancer Res 2001, 61:4842-4850
11. Abbott DW, Freeman ML, Holt JT: Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 1998, 90:978-985
12. Chen PL, Chen CF, Chen Y, Xiao J, Sharp ZD, Lee WH: The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci USA 1998, 95:5287-5292
13. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994, 8:27-32
14. Hahn SA, Seymour AB, Hoque AT, Schutte M. da Costa LT, Redston MS, Caldas C, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE: Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res 1995, 55:4670-4675
15. Ory DS, Neugeboren BA, Mulligan RC: A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci USA 1996, 93:11400-11406
16. Garcia-Higuera I, Kuang Y, Naf D, Wasik J, D'Andrea AD: Fanconi anemia proteins FANCA, FANCC, and FANCG/XRCC9 interact in a functional nuclear complex. Mol Cell Biol 1999, 19:4866-4873
17. Kuang Y, Garcia-Higuera I, Moran A, Mondoux M, Digweed M, D'Andrea AD: Carboxy terminal region of the Fanconi anemia protein, FANCG/XRCC9, is required for functional activity. Blood 2000, 96:1625-1632
18. Naf D, Kupfer GM, Suliman A, Lambert K, D'Andrea AD: Functional activity of the Fanconi anemia protein FAA requires FAC binding and nuclear localization. Mol Cell Biol 1998, 18:5952-5960
19. Meetei AR, de Winter JP, Medhurst AL, Wallisch M, Waisfisz Q, van de Vrugt HJ, Oostra AB, Yan Z, Ling C, Bishop CE, Hoatlin ME, Joenje H, Wang W: A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet 2003, 35:165-170
20. Gregory RC, Taniguchi T, D'Andrea AD: Regulation of the Fanconi anemia pathway by monoubiquitination. Semin Cancer Biol 2003, 13:77-82
21. D'Andrea AD, Grompe M: The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003, 3:23-34
22. Moynahan ME, Pierce AJ, Jasin M: BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001, 7:263-272
23. Sasaki MS, Tonomura A: A high susceptibility of Fanconi's anemia to chromosome breakage by DNA cross-linking agents. Cancer Res 1973, 33:1829-1836
24. Auerbach AD, Wolman SR: Susceptibility of Fanconi's anaemia fibroblasts to chromosome damage by carcinogens. Nature 1976, 261:494-496
25. Tutt A, Bertwistle D, Valentine J, Gabriel A, Swift S, Ross G, Griffin C, Thacker J, Ashworth A: Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 2001, 20:4704-4716
26. Kern SE, Hruban RH, Hidalgo M, Yeo CJ: An introduction to pancreatic adenocarcinoma genetics, pathology and therapy. Cancer Biol Ther 2002, 1:607-613
27. Hill RD: Familial cancer on a Scottish island. Br Med J 1976, 2:401-402
28. Heinrich MC, Hoatlin ME, Zigler AJ, Silvey KV, Bakke AC, Keeble WW, Zhi Y, Reifsteck CA, Grompe M, Brown MG, Magenis RE, Olson SB, Bagby GC: DNA cross-linker-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint function. Blood 1998, 91:275-287
29. Matsumoto A, Vos JM, Hanawalt PC: Repair analysis of mitomycin C-induced DNA crosslinking in ribosomal RNA genes in lymphoblastoid cells from Fanconi's anemia patients. Mutat Res 1989, 217:185-192
30. Akkari YM, Bateman RL, Reifsteck CA, D'Andrea AD, Olson SB, Grompe M: The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. Mol Genet Metab 2001, 74:403-412
31. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE, Herman JG: Abrogation of the Rb/p16 tumorsuppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997, 57:3126-3130
32. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, Kern SE: p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994, 54:3025-3033
33. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC, D'Andrea AD: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003, 9:568-574